Manufacturer
Servier
Contents
Per 1.5 mg/5 mg MR tab Indapamide 1.5 mg, amlodipine 5 mg
Indication
Substitution therapy for treatment of essential HTN in patients already controlled w/ indapamide & amlodipine given concurrently at same dose level.
Instruction
May be taken with or without food: Swallow whole w/ water. Do not chew.
Drug interaction
Indapamide: Increased plasma lithium. Increased risk of ventricular arrythmias w/ Torsades de pointes-inducing drugs eg, class Ia (quinidine, hydroquinidine, disopyramide) & III antiarrythmics (amiodarone, sotalol, dofetilide, ibutilide), some antipsychotics eg, phenothiazines (chlorpromazine, cyamemazine, levomepromazine, thioridazine, trifluoperazine), benzamides (amisulpride, sulpiride, sultopride, tiapride), butyrophenones (droperidol, haloperidol); bepridil, cisapride, diphemanil, erythromycin IV, halofantrine, mizolastine, pentamidine, sparfloxacin, moxifloxacin, vincamine IV. Reduced antihypertensive effect w/ NSAIDs (systemic route) including COX-2 selective inhibitors, high dose salicylic acid (≥3 g/day). Risk of sudden hypotension &/or acute renal failure w/ ACE inhibitors. Increased risk of hypokalaemia (additive effect) w/ amphotericin B (IV), gluco- & mineralocorticoids (systemic route), tetracosactide, stimulant laxatives. Increased antihypertensive effect w/ baclofen. Increase incidence of hypersensitivity reactions to allopurinol. Increased risk of metformin-induced lactic acidosis. Increased risk of acute renal failure w/ iodinated contrast media (large doses). Increased antihypertensive effect & risk of orthostatic hypotension w/ imipramine-like antidepressants & neuroleptics. Risk of hypercalcaemia w/ Ca (salts). Increased plasma creatinine w/ ciclosporin, tacrolimus. Decreased antihypertensive effect w/ corticosteroids, tetracosactide (systemic route). Digitalis prep, K-sparing diuretics (amiloride, spironolactone, triamterene). Amlodipine: Risk of hyperkalaemia w/ dantrolene (infusion). Increased bioavailability w/ grapefruit or grapefruit juice. Increased exposure w/ strong or moderate CYP3A4 inhibitors (PIs, azole antifungals, macrolides-like erythromycin or clarithromycin, verapamil or diltiazem). Decreased plasma conc w/ CYP3A4 inducers (eg, rifampicin, Hypericum perforatum). Additive BP-lowering effects of antihypertensives. Increased exposure of simvastatin.
Malaysia
